Table 1. Description of pediatric versus adult patients with PRES.
| All | Pediatric patients | Adult patients | p-value | |
| n | 110 | 19 | 91 | - |
| Age in years, median (IQR) | 36 (22–61) | 9 (7–12) | 48 (29–64) | - |
| Female sex, n (%) | 75 (68.1%) | 7 (36.8%) | 68 (74.7%) | - |
| Systolic BP in mmHG, median (IQR)* | 160 (140–180) | 140 (124–160) | 170 (150–180) | 0.001 |
| Age adjusted Arterial Hypertension, n (%) | 92 (83.6%) | 15 (78.9%) | 77 (84.6%) | 0.4 |
| Etiology/Toxic Association, n (%) | <0.001 | |||
| Immunosuppression | 25 (22.7%) | 3 (15.8%) | 22 (24.2%) | |
| BMT | 5 (4.5%) | 1 (5.3%) | 4 (0.4%) | |
| SOD | 20 (18.2%) | 2 (10.6%) | 18 (19.8%) | |
| Autoimmune Disorders | 22 (20.0%) | 11 (57.9%) | 11 (12.1%) | |
| Chemotherapy | 21 (19.1%) | 4 (21.1%) | 17 (18.7%) | |
| Pre-/Eclampsia | 25 (22.7%) | 0 | 25 (27.5%) | |
| Infection/sepsis | 6 (5.5%) | 0 | 6 (6.6%) | |
| Other/Unknown | 11 (10.0%) | 1 (5.3%) | 10 (11.0%) | |
| Initial Neurological Symptoms, n (%) | ||||
| Seizures | 78 (70.9%) | 18 (94.7%) | 60 (65.9%) | 0.01 |
| Visual Disturbances | 34 (30.9%) | 2 (10.5%) | 32 (35.0%) | 0.05 |
| Altered Mental State | 42 (38.2%) | 5 (26.3%) | 37 (40.7%) | 0.3 |
| Paresis | 16 (14.5%) | 4 (21.1%) | 12 (13.2%) | 0.47 |
| C-reactive Protein in mg/dl, mean ± SD | 4.2±6.4 | 1.7±2.4 | 4.8±6.8 | 0.01 |
| Creatinine in mg/dl, mean ± SD | 1.8±1.9 | 1.4±2.0 | 1.7±1.9 | 0.5 |
| Length of Hospital Stay in Days, median (IQR) | 41.2±40.6 | 50±52 | 39±37 | 0.2 |
Exact RR-levels at initial PRES toxicity missing in 3 patients (1 pediatric, 2 adult).